FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292372801> ?p ?o ?g. }

• W4292372801 abstract "Children with multi-drug resistant idiopathic nephrotic syndrome (MDR-INS) usually progress to end-stage kidney disease with a consistent risk of disease recurrence after transplantation. New therapeutic options are needed for these patients. Mesenchymal stromal cells (MSCs) are multipotential non-hematopoietic cells with several immunomodulatory properties and growing clinical applications. Cord blood-derived MSC have peculiar anti-inflammatory and immunosuppressive properties. We aimed at assessing safety and efficacy of cord-blood-derived MSCs (CB-MSCs) in children with MDR-INS.Prospective, open-label, single arm phase I-II pilot study. Pediatric patients with MDR-INS, resistant to at least two lines of therapy, were enrolled. Allogenic CB-MSCs were administered intravenously on days 0, 14, and 21 at a dose of 1.5 × 106 cells/kg. Patients were followed for at least 12 months. The primary outcomes were safety and toxicity. The secondary outcome was remission at 12 months evaluated by urinary protein/urinary creatinine ratio (uPr/uCr). Circulating regulatory T cells (Tregs) were monitored.Eleven pediatric patients with MDR-INS (10 females, median age 13 years) resistant to a median of 3 previous lines of therapy were enrolled. All patients completed the CB-MSC infusion schedule. No patient experienced any infusion-related adverse event or toxicity. Nine patients were assessable for efficacy. At the 12 months follow-up after the treatment, the median uPr/uCr did not change significantly from baseline (8.13 vs. 9.07; p = 0.98), while 3 patients were in partial or complete remission. A lower baseline uPr/uCr was a predictor of remission (2.55 vs. 8.74; p = 0.0238). Tregs count was not associated with CB-MSCs therapy.CB-MSCs are safe and may have a role in the immunosuppressive therapy of pediatric patients with MDR-INS. This preliminary experience paves the way toward further phase II studies addressing MSC efficacy in immune-mediated kidney diseases." @default.
• W4292372801 created "2022-08-20" @default.
• W4292372801 creator A5002211134 @default.
• W4292372801 creator A5005375378 @default.
• W4292372801 creator A5005897631 @default.
• W4292372801 creator A5011046178 @default.
• W4292372801 creator A5025540008 @default.
• W4292372801 creator A5030278312 @default.
• W4292372801 creator A5036524784 @default.
• W4292372801 creator A5039059487 @default.
• W4292372801 creator A5041378698 @default.
• W4292372801 creator A5047726979 @default.
• W4292372801 creator A5052659695 @default.
• W4292372801 creator A5053801317 @default.
• W4292372801 creator A5054844286 @default.
• W4292372801 creator A5056615921 @default.
• W4292372801 creator A5058529914 @default.
• W4292372801 creator A5067327708 @default.
• W4292372801 creator A5069788278 @default.
• W4292372801 creator A5077513353 @default.
• W4292372801 creator A5080328927 @default.
• W4292372801 creator A5084061745 @default.
• W4292372801 creator A5085070426 @default.
• W4292372801 date "2022-08-19" @default.
• W4292372801 modified "2023-10-14" @default.
• W4292372801 title "First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome" @default.
• W4292372801 cites W1763526952 @default.
• W4292372801 cites W1790809173 @default.
• W4292372801 cites W1967052290 @default.
• W4292372801 cites W1970600368 @default.
• W4292372801 cites W1985429617 @default.
• W4292372801 cites W1991118583 @default.
• W4292372801 cites W2025371271 @default.
• W4292372801 cites W2030581712 @default.
• W4292372801 cites W2035529078 @default.
• W4292372801 cites W2056510698 @default.
• W4292372801 cites W2069399162 @default.
• W4292372801 cites W2074744239 @default.
• W4292372801 cites W2078000231 @default.
• W4292372801 cites W2086673145 @default.
• W4292372801 cites W2095666785 @default.
• W4292372801 cites W2110192851 @default.
• W4292372801 cites W2118934189 @default.
• W4292372801 cites W2122855609 @default.
• W4292372801 cites W2126134953 @default.
• W4292372801 cites W2158879557 @default.
• W4292372801 cites W2159358845 @default.
• W4292372801 cites W2322691879 @default.
• W4292372801 cites W2337861353 @default.
• W4292372801 cites W2588009333 @default.
• W4292372801 cites W2594454279 @default.
• W4292372801 cites W2606230779 @default.
• W4292372801 cites W2768087778 @default.
• W4292372801 cites W2769010773 @default.
• W4292372801 cites W2773758370 @default.
• W4292372801 cites W2774129885 @default.
• W4292372801 cites W2775091487 @default.
• W4292372801 cites W2805661897 @default.
• W4292372801 cites W2808158796 @default.
• W4292372801 cites W2808503484 @default.
• W4292372801 cites W2883415588 @default.
• W4292372801 cites W2891467376 @default.
• W4292372801 cites W2951973537 @default.
• W4292372801 cites W2981176978 @default.
• W4292372801 cites W3012862268 @default.
• W4292372801 cites W3035715682 @default.
• W4292372801 cites W3137717449 @default.
• W4292372801 cites W1732997308 @default.
• W4292372801 doi "https://doi.org/10.1186/s13287-022-03112-7" @default.
• W4292372801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35986374" @default.
• W4292372801 hasPublicationYear "2022" @default.
• W4292372801 type Work @default.
• W4292372801 citedByCount "4" @default.
• W4292372801 countsByYear W42923728012023 @default.
• W4292372801 crossrefType "journal-article" @default.
• W4292372801 hasAuthorship W4292372801A5002211134 @default.
• W4292372801 hasAuthorship W4292372801A5005375378 @default.
• W4292372801 hasAuthorship W4292372801A5005897631 @default.
• W4292372801 hasAuthorship W4292372801A5011046178 @default.
• W4292372801 hasAuthorship W4292372801A5025540008 @default.
• W4292372801 hasAuthorship W4292372801A5030278312 @default.
• W4292372801 hasAuthorship W4292372801A5036524784 @default.
• W4292372801 hasAuthorship W4292372801A5039059487 @default.
• W4292372801 hasAuthorship W4292372801A5041378698 @default.
• W4292372801 hasAuthorship W4292372801A5047726979 @default.
• W4292372801 hasAuthorship W4292372801A5052659695 @default.
• W4292372801 hasAuthorship W4292372801A5053801317 @default.
• W4292372801 hasAuthorship W4292372801A5054844286 @default.
• W4292372801 hasAuthorship W4292372801A5056615921 @default.
• W4292372801 hasAuthorship W4292372801A5058529914 @default.
• W4292372801 hasAuthorship W4292372801A5067327708 @default.
• W4292372801 hasAuthorship W4292372801A5069788278 @default.
• W4292372801 hasAuthorship W4292372801A5077513353 @default.
• W4292372801 hasAuthorship W4292372801A5080328927 @default.
• W4292372801 hasAuthorship W4292372801A5084061745 @default.
• W4292372801 hasAuthorship W4292372801A5085070426 @default.
• W4292372801 hasBestOaLocation W42923728011 @default.
• W4292372801 hasConcept C126322002 @default.
• W4292372801 hasConcept C142724271 @default.
• W4292372801 hasConcept C197934379 @default.

• next